• Emergent BioSolutions Inc EBS.N, EBS is expected to show a fall in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

• The Gaithersburg Maryland-based company is expected to report a 27.1% decrease in revenue to $219 million from $300.4 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on March 3 2025, for the period ended March 31, was for revenue between $200.00 million and $240.00 million. (Sales/Revenue majority basis is on Total Revenue.)

• ​LSEG's mean analyst estimate for Emergent BioSolutions Inc is for earnings of 44 cents per share.

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50​, above​ its last closing price of $5.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 5 at 21:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)